Payment overview · 2025
General Payments
$64.25
4 reported records · 4 companies
Healthcare provider profile · identity verified
Debra J Wallace, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MORGANFIELD, KY · NPI 1033186911
Verified facts
What the public records show
CMS Open Payments records show Debra J Wallace, M.D. received $64.25 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.08 | 28.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.33 | 25.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.03 | 24.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.81 | 21.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $64.25 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 618 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 398 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 278 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 265 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 238 | 67 |
| Omeprazole | Omeprazole | 235 | 52 |
| Metformin Hcl | Metformin Hcl | 233 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 232 | 51 |
| Simvastatin | Simvastatin | 215 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 45 |
| Benazepril Hcl | Benazepril Hcl | 195 | 44 |
| Gabapentin | Gabapentin | 190 | 63 |
| Lisinopril | Lisinopril | 181 | 49 |
| Meloxicam | Meloxicam | 180 | 49 |
| Losartan Potassium | Losartan Potassium | 159 | 40 |
| Jardiance | Empagliflozin | 121 | 30 |
| Furosemide | Furosemide | 118 | 37 |
| Buspirone Hcl | Buspirone Hcl | 109 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 29 |
| Tramadol Hcl | Tramadol Hcl | 100 | 21 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 97 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 24 |
| Allopurinol | Allopurinol | 95 | 19 |
| Alprazolam | Alprazolam | 93 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 25 |
| Lorazepam | Lorazepam | 85 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 22 |
| Montelukast Sodium | Montelukast Sodium | 74 | 17 |
| Farxiga | Dapagliflozin Propanediol | 71 | 16 |
| Mirtazapine | Mirtazapine | 71 | 12 |
| Donepezil Hcl | Donepezil Hcl | 67 | 18 |
| Atenolol | Atenolol | 66 | 16 |
| Ozempic | Semaglutide | 66 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 65 | 18 |
| Warfarin Sodium | Warfarin Sodium | 65 | 12 |
| Memantine Hcl | Memantine Hcl | 64 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 62 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 42 |
| Prednisone | Prednisone | 56 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Potassium Chloride | Potassium Chloride | 54 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 14 |
| Azithromycin | Azithromycin | 52 | 47 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 51 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 12 |
| Temazepam | Temazepam | 50 | 16 |
| Eliquis | Apixaban | 49 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 13 |
| Glipizide | Glipizide | 46 | 13 |
| Januvia | Sitagliptin Phosphate | 45 | 14 |
| Trazodone Hcl | Trazodone Hcl | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 36 |
| Rybelsus | Semaglutide | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 13 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | 13 |
| Gemtesa | Vibegron | 35 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Etodolac | Etodolac | 30 | 12 |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 26 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Estradiol | Estradiol | 26 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 18 |
| Ramipril | Ramipril | 22 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Verapamil Hcl | Verapamil Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Glyburide Micronized | Glyburide,micronized | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Flavoxate Hcl | Flavoxate Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Metronidazole | Metronidazole | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64.25 · 4 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, NURTEC ODT, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error